First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®
Medivir AB (Nasdaq Stockholm: MVIR) announced the initiation of treatment for the first patient with hepatocellular carcinoma (HCC) in the phase 2a trial of fostroxacitabine bralpamide (fostrox) in combination with Lenvima®.
This trial is part of an ongoing multicenter study aimed at patients with HCC who have not responded to or cannot tolerate existing therapies. Preliminary results from the phase 1b study indicate that fostrox has a favorable safety profile. The recommended dose for the combination with Lenvima® has been established at 30 mg, and the study aims to recruit up to 30 patients across clinics in Great Britain, Spain, and South Korea.
- Initiation of phase 2a trial for fostrox in combination with Lenvima.
- Positive preliminary results from phase 1b study with good safety profile.
- None.
In Medivir's ongoing phase 1b/2a study, fostrox is given in combination with two other drugs, either with Lenvima®, a tyrosine kinase inhibitor, or with Keytruda®, an anti-PD-1 checkpoint inhibitor. The study is an open-label, multicenter study and includes patients with HCC for whom current first- or second-line treatment has proven ineffective or is not tolerable. The phase 1b part of the study evaluates which dose of fostrox is most appropriate for the next phase. This dose is then used in the phase 2a part of the study where safety and signals of efficacy are further evaluated.
The preliminary results from the recently completed phase 1b for fostrox in combination with Lenvima® were positive with a good safety and tolerability profile where no dose-limiting toxicity was observed. The recommended dose (RP2D) for fostrox in this combination arm was set at 30 mg.
"It is really exciting that we have been able to start the important expansion phase of the study so quickly, with the first patient now being treated with fostrox and Lenvima® in phase 2a. The medical need for a new, effective treatment is immense and so is the interest from both investigators and patients, which is why I believe that the recruitment of patients to this part of the study will be completed swiftly," says
The results from this study will form the basis for the future development plan for fostrox. A total of up to 30 patients with HCC are planned to be recruited in the study that is being conducted at 14 clinics in
For additional information, please contact
Telephone: +46 8 5468 3100.
E-mail: magnus.christensen@medivir.com
About fostrox
Fostrox is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostrox has completed a phase 1b monotherapy study, and a combination study in HCC currently ongoing.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/first-patient-dosed-in-the-phase-2a-part-of-medivirs-study-with-fostrox-in-combination-with-lenvima-301771233.html
SOURCE Medivir
FAQ
What is the purpose of Medivir's phase 2a trial for fostrox?
What were the results of the phase 1b study for fostrox?
How many patients are being recruited in the phase 2a study?
Which countries are participating in the fostrox study?
What is the significance of the fostrox trial for cancer treatment?
